Easy CDMO

Products

SRT 1720 HCl

CAS No.: 1001645-58-4

Category

Cat.NO.:A1165814  Purity:98%

Product Details of SRT 1720 HCl

CAS No. : 1001645-58-4
Formula :

C25H23N7OS.xHCl

M.W :

506.02

SMILES Code :
O=C(NC1=CC=CC=C1C2=CN3C(SC=C3CN4CCNCC4)=N2)C5=NC6=CC=CC=C6N=C5.[H]Cl
Synonyms :
SRT1720; SIRT-1933; CAY10559
MDL No. : MFCD18074509
InChI Key : DTGRRMPPXCRRIM-UHFFFAOYSA-N
Pubchem ID : 25232708

Safety of SRT 1720 HCl

GHS Pictogram:
Signal Word: Warning
Hazard Statements: H302-H315-H319-H335
Precautionary Statements: P261-P305+P351+P338

Related Pathways of SRT 1720 HCl

epigenetics

Isoform Comparison

Biological Activity

In Vitro:

Cell Line

Concentration Treated Time Description References
primary hepatocytes 1 µM 1 hour Induction of SIRT1 activity reduced amounts of acetylated CRTC2 and lowered Ad-CRE-luc activity PMC2597669
HepG2 cells 5 μM SRT1720 increases FGF21 protein production and elevates CPT1α gene expression, while also increasing mitochondrial oxygen consumption rate (OCR) PMC4228483
IDG-SW3 cells 1 µM 5 days SRT1720 treatment increased the osteogenic differentiation capacity of IDG-SW3 cells and decreased sclerostin expression levels. PMC6028485
MDS-L cells 2.5 µM 96 hours To evaluate the effect of SRT1720 on the viability of MDS-L cells, results showed that SRT1720 treatment inhibited the growth of MDS-L cells. PMC6143172
MDS CD34+ cells 2.5 µM 72 hours To evaluate the effect of SRT1720 on the colony-forming ability of MDS CD34+ cells, results showed that SRT1720 treatment significantly reduced the colony formation of MDS CD34+ cells. PMC6143172

In Vivo:

Species

Animal Model

Administration Dosage Frequency Description References
Mice Activity-based anorexia (ABA) model Intraperitoneal injection 3 mg/kg Single injection, lasting 4 hours SRT1720 made mice more susceptible to the ABA model, resulting in faster weight loss. PMC7272424
mice wild-type mice intraperitoneal injection 50 mg/kg/day once a day, 5 days per week, for 4 consecutive weeks SRT1720 treatment resulted in increased bone mass, decreased sclerostin expression, and enhanced WNT/β-catenin signaling in wild-type mice. PMC6028485
Mice NSGS mice Oral 100 mg/kg once daily for 10 consecutive days To evaluate the effect of SRT1720 on the engraftment of MDS-L cells in NSGS mice, results showed that SRT1720 treatment significantly reduced the engraftment of MDS-L cells in the bone marrow. PMC6143172
Mice Emphysema model Oral 100 mg/kg/day Once daily for 2 weeks SRT1720, by activating SIRT1, attenuated elastase-induced airspace enlargement and lung function impairment, and improved arterial oxygen saturation. PMC3366403
mice NSGS mice oral 100 mg/kg Once daily for 10 weeks To evaluate the effect of SRT1720 on the engraftment of MDS-L cells in NSGS mice, results showed that SRT1720 treatment significantly reduced the engraftment of MDS-L cells PMC6143172
Mice Activity-based anorexia (ABA) model Intraperitoneal injection 100 mg/kg/day once daily for 2 weeks SRT1720 activates SIRT1, accelerating ABA phenotypes and making mice more susceptible to ABA-related behaviors. PMC7272424
Mice Emphysema model Oral 35 mg/kg Once daily for 30 days SRT1720 attenuated elastase-induced airspace enlargement and lung function impairment as well as improved arterial oxygen saturation during emphysema development. PMC3366403

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.98mL

0.40mL

0.20mL

9.88mL

1.98mL

0.99mL

19.76mL

3.95mL

1.98mL

References

 

Details

Reviews

There are no reviews yet.

Be the first to review “SRT 1720 HCl”

Your email address will not be published. Required fields are marked *